MedTrace Logo

Single Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations

NCT00388219 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2007-07-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether Transtec (R) PRO 70 µg/h and a new buprenorphine patch formulation lead to same plasma levels of buprenorphine after single dose application

Conditions

  • Healthy

Interventions

DRUG

Transtec (R) PRO (buprenorphine)

Sponsors & Collaborators

  • Grünenthal GmbH

    lead INDUSTRY

Principal Investigators

  • Dr. Baumann-Noss, MD · IKP Mannheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Completion
2006-11-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00388219 on ClinicalTrials.gov